📰 Hookipa Pharma News
Page 2 - Hookipa Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hookipa Pharma. Real-time updates on events, politics, business and more.
February 2, 2024
Check out this week’s medical marketing news, people on the move and industry chatter.
January 30, 2024
Hookipa Pharma Inc.’s nearly $1 billion collaboration with Roche Holding AG dissolved along with 30% of the company’s staff. The New York-based company said Roche ended the October 2022 deal involving the HB-700 program in treating KRAS mutated cancers but did not say why the agreement fell apart.
January 29, 2024
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...
December 26, 2023
Shares of Hookipa Pharma Inc (NASDAQ:HOOK – Get Free Report) were down 16.5% during mid-day trading on Monday . The stock traded as low as $0.71 and last traded at $0.72. Approximately 9,262,100 shares were traded during trading, an increase of 749% from the average daily volume of 1,090,797 shares. The stock had previously closed […]
December 21, 2023
By Dean Seal Shares of HOOKIPA Pharma surged after the company said Gilead Sciences bought 15 million of its shares at about $1.42 apiece. The stock was up...
November 9, 2023
Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial expected to start in 2024 Published peer-reviewed preclinical data, in collaboration with Gilead Sciences, for HB-400 program in The Journal of Infectious Disease Recruitment ongoing for two Phase 1 clinical trials
October 1, 2023
Royal Bank of Canada reiterated their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research report released on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has a $7.00 target price on the stock. Several other equities research analysts have also issued reports on HOOK. HC Wainwright lowered their […]
September 10, 2023
Truist Financial restated their buy rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Several other brokerages have also issued reports on HOOK. Royal Bank of Canada reissued an outperform rating and issued a $7.00 […]
August 15, 2023
One thing we could say about the analysts on HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) - they aren't optimistic, having just...
August 13, 2023
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.01), reports. The company had revenue of $2.68 million during the quarter, compared to the consensus estimate of $3.54 million. Hookipa Pharma had a […]